New drug combo vs standard therapy for KRAS G12C lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB/IV) non-squamous non-small cell lung cancer
- Your cancer has a specific KRAS G12C mutation confirmed by a central lab
- You are between 18 and 80 years old
- You have not had any prior treatment for advanced or metastatic lung cancer
- You are in good enough health to be up and about (ECOG 0-1) and have adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This trial tests an experimental drug called RX001 for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change (KRAS mutation) and has stopped responding to standard treatments. The goal is to see if RX001 is safe and tolerable.
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.